Back to search
FDAFDA · Food and drugs·Recall number D-1088-2023

Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08

Published August 30, 2023 · Recall initiated: July 21, 2023

Summary

FDA records drug Class II recall D-1088-2023, published August 30, 2023 and initiated July 21, 2023. Recalling firm: Aurobindo Pharma USA Inc.; Status: Terminated; Reported quantity: 48 bottles; Lot: Lot #: RB4023002A, Exp 02/2025. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

cGMP deviations: Batch was released prior to approval.

What to do

Voluntary: Firm initiated · Letter

Get an email if RUFINAMIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
RUFINAMIDE
Manufacturer
Aurobindo Pharma USA Inc.
Distributor
USA nationwide
UPC
0359651616086
Lot
Lot #: RB4023002A, Exp 02/2025
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Rufinamide Tablets, USP 400 mg, packaged in 120-count bottle, Rx only, Distributed by: Aurobindo Pharma USA, Inc., 279 Princeton-Hightstown Road, East Windsor, NJ 08520, Made in India, NDC 59651-617-08 recalled?

Yes. FDA published recall D-1088-2023 on August 30, 2023. Reported hazard: cGMP deviations: Batch was released prior to approval.

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: RUFINAMIDE. UPC: 0359651616086.